IMS Health Inc.

Notable 52-Week NYSE New Highs and Lows 11/19: CAH, DCI, RX, KG, MRK, TSL Highs; SNV, WNR Low

StreetInsider.com News Articles (Free subscription) | 19/11/2009

Notable 52-week Highs on the NYSE: Cardinal Health, Inc. (NYSE: CAH) - Hit $31.77. UBS initiated coverage with a Buy rating on Cardinal. Donaldson Company Inc. (NYSE: DCI) - touched $45.09. The company reported Q110 earnings about the Street estimates today. IMS Health Inc. (NYSE: RX) - reached $21.65 King Pharmaceuticals Inc. (NYSE: KG) - hit $11.88. May be benefitting from mixed ZymoGenetics ratings...

Par Pharmaceutical Receives Final Approval to Market Generic Ultram(R) ER

PR News Wire (Free subscription) | 16/11/2009

WOODCLIFF LAKE, N.J., Nov. 16 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for the 100mg and 200mg strengths of tramadol ER. Ortho-McNeil sells extended-release tramadol tablets under the brand name Ultram® ER. Par has been awarded 180...

IMS deal questioned

New York Post (Free subscription) | 14/11/2009

The biggest leveraged buyout of 2009 could have been bigger, and investors may be the poorer for it. According to people familiar with the matter, pharmaceutical data company IMS Health might have been sold for more than the $5.2 billion price tha...

IMS Health Merger Likely to Close

SeekingAlpha.com (Free subscription) | 13/11/2009

On 05-Nov-09 IMS Health Inc ( RX ), the US healthcare information company, announced it had signed an agreement to be acquired by TPG Capital and the Canada Pension Plan Investment Board for USD 22 cash a share. The agreement was unanimously approved by the IMS Board, and comes after IMS announced on 20-Oct-09 it was exploring a variety of strategic alternatives for the company. The transaction has...

MAGIC FORMULA BUYOUTS and BANKRUPTCIES 2009: IMS Health and Marvel Entertainment, etc.

GuruFocus Updates (Free subscription) | 12/11/2009

By Steve Alexander. It should come as little surprise that many stocks that make it into the Magic Formula Investing (MFI) screen are attractive acquisition targets. Many, if not most, are good businesses selling at cheap prices, exactly what the screen is designed to find. When you have quality selling cheap, not only individual investors but business managers, both public and private, take notice...

IMS Health to Launch Oncology Quantifier

Industry Analyst Reporter News (Free subscription) | 12/11/2009

IMS Health (NYSE: RX), a provider of market intelligence to the pharmaceutical and healthcare industries, today announced the upcoming launch of IMS Oncology QuantifierTM.

Big Pharma deal with White House expected to net billions for drug industry

AMERICAblog (Free subscription) | 11/11/2009

Sam Stein at the Huffington Post : The deal struck between the pharmaceutical lobby, the White House and Senate Democrats has drastically improved Big Pharma's expected profits, a private industry report finds. IMS Health, a company that supplies the pharmaceutical companies with sales data, predicts that new health reform legislation -- combined with a projected upswing in the economy -- will result...

• Pharma Deal With White House on Course to Net Industry Billions - Vox Verax
• Pharma Deal With White House on Course to Net Industry Billions - The Huffington Post
• See the 4 articles on the same subject

WSJ: Motorola seeking buyer for Horsham set-top box business

Philadelphia Tech News (Free subscription) | 11/11/2009

The Wall Street Journal is reporting that Motorola is seriously seeking buyers for its set-top box business, based in Horsham. This is not a surprise, since such a move was generally thought to be part of Motorola's strategic plan; it just indicates that they may be getting close to evaluating actual bids. Private Equity buyers including TPG, which last week announced an agreement to purchase IMS Health,...

ObamaCare’s ‘Sweetheart Deal’ for PhRMA

Cato-at-liberty (Free subscription) | 11/11/2009

The New Republic’s Jonathan Cohn reports that back in March, IMS Health projected slightly negative revenue growth for the pharmaceutical industry but recently changed that projection to 3.5-percent annual growth from 2008 through 2013. “What changed'” Cohn asks. “A major factor, according to IMS, was the emerging details of health care reform . . . Put [...]

Big Pharma's Cut of Health Care "Reform"

The Agonist (Free subscription) | 11/11/2009

The New Republic of all places has the story: Critics have complained that a drug industry got a sweetheart deal when it struck a bargain with the White House and Senate Finance Committee over health care reform. There’s new reason to think those critics were right. It comes from an October forecast by IMS Health, a respected global research and consulting firm. The report, which IMS distributed...

IMS Health to Launch Oncology Quantifier, Delivering Integrated Insights for Enhanced Market Measurement, Commercial Strategies

Business Wire (Free subscription) | 11/11/2009

NORWALK, Conn.--(BUSINESS WIRE)--IMS Health (NYSE: RX), the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the upcoming launch of IMS Oncology QuantifierTM, a comprehensive, clinically rich analytical tool that enables the company’s clients to assess treatment opportunities and guide commercial decisions in the $48 billion...

Generic Prevacid SoluTab Is Here – Teva Wins Court Battle on Patent Challenge For Heartburn Drug

The Medical Quack (Free subscription) | 11/11/2009

How long is a drug patent going to last? This is a big question here today with Teva and Mylan being able to start marketing the generic version tomorrow. For us the patients, another big saver in the pharma area if you take Prevacid. The difference in this case, the drug dissolves differently than the one that is or was under patent, actually the patent is still in place but not sure how much good...

KKR guns for a military deal -- buys Northrop Grumman's TASC

BloggingStocks (Free subscription) | 09/11/2009

Filed under: Deals , Private equity , Northrop Grumman (NOC) Could it be that private-equity buyouts are making a comeback? There are certainly signs of a return. Just last week, TPG and the Canada Pension Plan agreed to shell out $4 billion for IMS Health ( RX ). This week, we have another interesting deal: KKR and General Atlantic will buy TASC for $1.65 billion. TASC is the consulting unit of Northrop...

Law Offices of Howard G. Smith Announces Investigation On Behalf of Shareholders of IMS Health, Inc.

Business Wire (Free subscription) | 06/11/2009

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that it is investigating potential claims against the board of directors of IMS Health, Inc. (“IMS” or the “Company”) (NYSE:RX) for possible breaches of fiduciary duty and other violations of state law in connection with their attempt to sell the Company to TPG Capital (“TPG”) and the CPP Investment...

Kendall Law Group Investigating IMS Health Inc. Takeover for Shareholders

Business Wire (Free subscription) | 06/11/2009

DALLAS--(BUSINESS WIRE)--Kendall Law Group, founded by a former federal judge, began an investigation on behalf of IMS Health Inc. (NYSE: RX) shareholders. The investigation concerns possible breaches of fiduciary duty by the Board of Directors in connection with the proposed acquisition by private equity firm Texas Pacific Group and the CPP Investment Board of Toronto. The transaction is valued at...